Author pages are created from data sourced from our academic publisher partnerships and public sources.
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
- E. Brunt, C. Janney, A. Bisceglie, B. A. Neuschwander-Tetri, B. Bacon
- American Journal of Gastroenterology
- 1 September 1999
OJECTIVE:Steatohepatitis is a morphological pattern of liver injury that may be seen in alcoholic or nonalcoholic liver disease. This pattern may occur with obesity, diabetes, the use of certain… Expand
Boceprevir for untreated chronic HCV genotype 1 infection.
BACKGROUND Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of… Expand
Boceprevir for previously treated chronic HCV genotype 1 infection.
BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are… Expand
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
- J. McHutchison, E. Lawitz, +17 authors M. Sulkowski
- The New England journal of medicine
- 10 December 2009
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these… Expand
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
BACKGROUND Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for… Expand
Nonalcoholic steatohepatitis: an expanded clinical entity.
BACKGROUND/AIMS In the past, nonalcoholic steatohepatitis has been described mostly in obese women with diabetes. The aim of this study was to describe a series of patients with nonalcoholic… Expand
Superparamagnetic iron oxide: pharmacokinetics and toxicity.
- R. Weissleder, David D. Stark, +5 authors J. Lewis
- AJR. American journal of roentgenology
The pharmacokinetics (distribution, metabolism, bioavailability, excretion) and toxicity (acute and subacute toxicity, mutagenicity) of a superparamagnetic iron oxide preparation (AMI-25), currently… Expand
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone
Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving IR would improve the… Expand
Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association.
HFE gene knockout produces mouse model of hereditary hemochromatosis.
- X. Zhou, S. Tomatsu, +12 authors W. Sly
- Medicine, Biology
- Proceedings of the National Academy of Sciences…
- 3 March 1998
Hereditary hemochromatosis (HH) is a common autosomal recessive disease characterized by increased iron absorption and progressive iron storage that results in damage to major organs in the body.… Expand